Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adding cisplatin to gemcitabine improves treatment of advanced pancreatic carcinoma

The combination of cisplatin and gemcitabine improves the outcome in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas, compared to gemcitabine alone, claims a team from Italy.

News image

fiogf49gjkf04

The researchers conducted a Phase III trial to compare gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma.

They published their results in the 15 February issue of Cancer.

Time to disease progression and the clinical benefit rate were determined.

The objective response rate, overall survival rate, and toxicity patterns of patients in the two treatment arms were evaluated as secondary end points

A total of 107 patients were randomized to receive gemcitabine (Arm A, n = 54) or a combination of gemcitabine and cisplatin (Arm B, n = 53).

In Arm A, a dose of 1000 mg/m2 gemcitabine per week was administered for 7 consecutive weeks. After a 2-week rest, treatment was resumed on Days 1, 8, and 15, of a 28-day cycle for 2 cycles.

In Arm B, cisplatin was given at a dose of 25 mg/m2 per week, 1 hour before gemcitabine, at the same dose that was used in Arm A. On Day 22, only gemcitabine was administered.

Patients were restaged after the first 7 weeks of therapy, and then again after the other 2 cycles.

The median time to disease progression was found to be 8 weeks in Arm A, and 20 weeks in Arm B.

In Arm A, 1 complete response and 4 partial responses were recorded on the basis of an intent-to-treat analysis, with an overall response rate of 9%.

Response rate:
Gemcitabine alone: 9%
Gemcitabine plus cisplatin: 26%
Cancer

In Arm B, there were no complete responses, whereas 14 partial responses were achieved, with an overall response rate of 26%.

This difference in the overall response rates was statistically significant.

The researchers found that the tumor growth control rate (total number of patients who achieved complete responses, partial responses, and stable disease) was 43% in Arm A and 57% in Arm B.

A clinical benefit was observed in 21 of 43 patients (49%) in Arm A and in 20 of 38 patients (53%) in Arm B, without any significant difference.

The median overall survival was 20 weeks for patients in Arm A, and 30 weeks for patients in Arm B.

Toxicity was mild in both treatment arms, with no significant differences between the two groups. However, there was a statistically higher incidence of Grade 1-2 asthenia in Arm B.

Dr Giuseppe Colucci, of the Oncology Institute in Bari, said on behalf of the group, "The addition of cisplatin to gemcitabine significantly improved the median time to disease progression and the overall response rate, compared with gemcitabine alone.

"The clinical benefit rate was similar in both arms. However, the median overall survival rate was more favorable for Arm B, although the difference did not attain statistical significance."

"The combination of cisplatin and gemcitabine currently may be considered as an optimal treatment for patients with locally advanced and/or metastatic adenocarcinoma of the pancreas," it was concluded.

Cancer 2002; 94(4): 902-10
01 March 2002

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us